Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus.
作者信息
Pfaller M A, Diekema D J
机构信息
Department of Pathology, College of Medicine, University of Iowa, Iowa City, Iowa 52242, USA.
出版信息
J Clin Microbiol. 2004 Oct;42(10):4419-31. doi: 10.1128/JCM.42.10.4419-4431.2004.
Abstract
摘要
相似文献
1
Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus.
J Clin Microbiol. 2004 Oct;42(10):4419-31. doi: 10.1128/JCM.42.10.4419-4431.2004.
2
[Nosocomial urinary infection due to Trichosporon asahii. First two cases in Chile].
Rev Iberoam Micol. 2003 Mar;20(1):21-3.
3
Emerging moulds: epidemiological trends and antifungal resistance.
Mycoses. 2011 Nov;54(6):e666-78. doi: 10.1111/j.1439-0507.2011.02032.x. Epub 2011 Jun 14.
4
Changing epidemiology of systemic fungal infections.
Clin Microbiol Infect. 2008 May;14 Suppl 4:5-24. doi: 10.1111/j.1469-0691.2008.01978.x.
5
Recent advances and challenges in the treatment of invasive fungal infections.
Int J Antimicrob Agents. 2007 Dec;30(6):487-95. doi: 10.1016/j.ijantimicag.2007.07.019. Epub 2007 Oct 24.
6
In vitro susceptibility testing in fungi: a global perspective on a variety of methods.
Mycoses. 2010 Jan;53(1):1-11. doi: 10.1111/j.1439-0507.2009.01813.x.
7
Antimicrobial activity of omiganan pentahydrochloride against contemporary fungal pathogens responsible for catheter-associated infections.
Antimicrob Agents Chemother. 2008 Mar;52(3):1187-9. doi: 10.1128/AAC.01475-07. Epub 2008 Jan 7.
8
New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance.
Expert Rev Anti Infect Ther. 2009 Oct;7(8):981-98. doi: 10.1586/eri.09.67.
9
PCR and single-strand conformational polymorphism for recognition of medically important opportunistic fungi.
J Clin Microbiol. 1995 Dec;33(12):3216-20. doi: 10.1128/jcm.33.12.3216-3220.1995.
10
Emerging and less common fungal pathogens.
Infect Dis Clin North Am. 2002 Dec;16(4):915-33, vi-vii. doi: 10.1016/s0891-5520(02)00041-7.
引用本文的文献
1
Invasive fungal infections caused by rare yeast-like fungi in adult patients: results of a prospective study.
Curr Med Mycol. 2024 Dec 31;10. doi: 10.22034/cmm.2025.345265.1559. eCollection 2024.
2
Characterization of Virulence Factors, Cellular Stress Response, and Antifungal Susceptibility Testing of spp. Isolated from Northeast Brazilian Patients.
J Fungi (Basel). 2025 Mar 26;11(4):255. doi: 10.3390/jof11040255.
3
Exploring the Biology, Virulence, and General Aspects of .
Infect Drug Resist. 2024 Dec 21;17:5755-5773. doi: 10.2147/IDR.S497862. eCollection 2024.
4
Chemical Profiling by High-Performance Liquid Chromatography With Diode Array Detection and Gas Chromatography-Mass Spectrometry Analysis and Antimicrobial Potential of Achillea santolina Plant Extracts against Extended-Spectrum Beta-Lactamase-producing Escherichia coli and Fungal Pathogens.
Chem Biodivers. 2025 May;22(5):e202403064. doi: 10.1002/cbdv.202403064. Epub 2025 Jan 20.
5
Advances in Dendritic-Cell-Based Vaccines against Respiratory Fungal Infections.
Vaccines (Basel). 2024 Aug 28;12(9):981. doi: 10.3390/vaccines12090981.
6
Navigating the fungal battlefield: cysteine-rich antifungal proteins and peptides from Eurotiales.
Front Fungal Biol. 2024 Sep 3;5:1451455. doi: 10.3389/ffunb.2024.1451455. eCollection 2024.
7
Rethinking Aspergillosis in the Era of Microbiota and Mycobiota.
Mycopathologia. 2024 Jun 12;189(4):49. doi: 10.1007/s11046-024-00853-2.
8
Impact of Lysine Succinylation on the Biology of Fungi.
Curr Issues Mol Biol. 2024 Jan 23;46(2):1020-1046. doi: 10.3390/cimb46020065.
9
activity of manogepix and comparators against infrequently encountered yeast and mold isolates from the SENTRY Surveillance Program (2017-2022).
Antimicrob Agents Chemother. 2024 Feb 7;68(2):e0113223. doi: 10.1128/aac.01132-23. Epub 2024 Jan 11.
10
Inhibitors of 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase Decrease the Growth, Ergosterol Synthesis and Generation of Mutants in and .
Int J Mol Sci. 2023 Nov 28;24(23):16868. doi: 10.3390/ijms242316868.
本文引用的文献
1
Activities of available and investigational antifungal agents against rhodotorula species.
J Clin Microbiol. 2005 Jan;43(1):476-8. doi: 10.1128/JCM.43.1.476-478.2005.
2
Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis.
Clin Infect Dis. 2004 Aug 15;39(4):584-7. doi: 10.1086/422723. Epub 2004 Jul 30.
3
Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the ARTEMIS Antifungal Surveillance Program conducted in 2001 and 2002.
J Clin Microbiol. 2004 Jul;42(7):3142-6. doi: 10.1128/JCM.42.7.3142-3146.2004.
4
Cross-resistance between fluconazole and ravuconazole and the use of fluconazole as a surrogate marker to predict susceptibility and resistance to ravuconazole among 12,796 clinical isolates of Candida spp.
J Clin Microbiol. 2004 Jul;42(7):3137-41. doi: 10.1128/JCM.42.7.3137-3141.2004.
5
Further standardization of broth microdilution methodology for in vitro susceptibility testing of caspofungin against Candida species by use of an international collection of more than 3,000 clinical isolates.
J Clin Microbiol. 2004 Jul;42(7):3117-9. doi: 10.1128/JCM.42.7.3117-3119.2004.
6
Fusarium infection in hematopoietic stem cell transplant recipients.
Clin Infect Dis. 2004 May 1;38(9):1237-42. doi: 10.1086/383319. Epub 2004 Apr 15.
7
In vitro activity of anidulafungin against selected clinically important mold isolates.
Antimicrob Agents Chemother. 2004 May;48(5):1912-5. doi: 10.1128/AAC.48.5.1912-1915.2004.
8
Mechanism of increased fluconazole resistance in Candida glabrata during prophylaxis.
Antimicrob Agents Chemother. 2004 May;48(5):1773-7. doi: 10.1128/AAC.48.5.1773-1777.2004.
9
Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program.
J Clin Microbiol. 2004 Apr;42(4):1519-27. doi: 10.1128/JCM.42.4.1519-1527.2004.
10
In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program.
Diagn Microbiol Infect Dis. 2004 Mar;48(3):201-5. doi: 10.1016/j.diagmicrobio.2003.09.008.
Zotero 插件